Shattuck Labs (NASDAQ:STTK – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.
Institutional & Insider Ownership
58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Shattuck Labs has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for Shattuck Labs and Aurinia Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shattuck Labs | 1 | 0 | 9 | 3 | 3.08 |
| Aurinia Pharmaceuticals | 0 | 3 | 2 | 1 | 2.67 |
Shattuck Labs currently has a consensus target price of $13.70, indicating a potential upside of 152.77%. Aurinia Pharmaceuticals has a consensus target price of $17.67, indicating a potential upside of 7.01%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Shattuck Labs is more favorable than Aurinia Pharmaceuticals.
Valuation and Earnings
This table compares Shattuck Labs and Aurinia Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shattuck Labs | $1.00 million | 543.95 | -$48.81 million | ($0.51) | -10.63 |
| Aurinia Pharmaceuticals | $283.05 million | 7.76 | $287.20 million | $2.29 | 7.21 |
Aurinia Pharmaceuticals has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Shattuck Labs and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shattuck Labs | N/A | -43.57% | -40.90% |
| Aurinia Pharmaceuticals | 100.84% | 26.11% | 19.89% |
Summary
Aurinia Pharmaceuticals beats Shattuck Labs on 9 of the 15 factors compared between the two stocks.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
